Abstract
As proof that cancers can occur in essentially any cell type, antigen-presenting cells (e.g., dendritic cells or Langerhans cells) can form cancers. Since these tumors can arise from lymph nodes, but do not arise from lymphocytes themselves, they are sometimes termed sarcomas. Other pathologists use the more noncommittal term “tumor” instead of “sarcoma” in this context. If anything, sustentacular tumors of lymphatic tissue represent the correct use of the term “histiocytic sarcoma,” as opposed to malignant fibrous histiocytoma (MFH, now termed undifferentiated pleomorphic sarcoma [UPS]), which are not composed of histiocytes, as are these tumors.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsReferences
Fonseca R, Yamakawa M, Nakamura S, et al. Follicular dendritic cell sarcoma and interdigitating reticulum cell sarcoma: a review. Am J Hematol. 1998;59:161–7.
Pileri SA, Grogan TM, Harris NL, et al. Tumours of histiocytes and accessory dendritic cells: an immunohistochemical approach to classification from the International Lymphoma Study Group based on 61 cases. Histopathology. 2002;41:1–29.
Grogg KL, Lae ME, Kurtin PJ, et al. Clusterin expression distinguishes follicular dendritic cell tumors from other dendritic cell neoplasms: report of a novel follicular dendritic cell marker and clinicopathologic data on 12 additional follicular dendritic cell tumors and 6 additional interdigitating dendritic cell tumors. Am J Surg Pathol. 2004;28:988–98.
Perkins SM, Shinohara ET. Interdigitating and follicular dendritic cell sarcomas: a SEER analysis. Am J Clin Oncol. 2013;36:395–8.
Gounder M, Desai V, Kuk D, et al. Impact of surgery, radiation and systemic therapy on the outcomes of patients with dendritic cell and histiocytic sarcomas. Eur J Cancer. 2015;51:2413–22.
Go H, Jeon YK, Huh J, et al. Frequent detection of BRAF(V600E) mutations in histiocytic and dendritic cell neoplasms. Histopathology. 2014;65:261–72.
Zhang H, Maitta RW, Bhattacharyya PK, et al. gamma-Synuclein is a promising new marker for staining reactive follicular dendritic cells, follicular dendritic cell sarcoma, Kaposi sarcoma, and benign and malignant vascular tumors. Am J Surg Pathol. 2011;35:1857–65.
Vermi W, Lonardi S, Bosisio D, et al. Identification of CXCL13 as a new marker for follicular dendritic cell sarcoma. J Pathol. 2008;216:356–64.
Xie Q, Chen L, Fu K, et al. Podoplanin (d2-40): a new immunohistochemical marker for reactive follicular dendritic cells and follicular dendritic cell sarcomas. Int J Clin Exp Pathol. 2008;1:276–84.
Mongkonsritragoon W, Li CY, Phyliky RL. True malignant histiocytosis. Mayo Clin Proc. 1998;73:520–8.
Elghetany MT. True histiocytic lymphoma: is it an entity? Leukemia. 1997;11:762–4.
Soria C, Orradre JL, Garcia-Almagro D, et al. True histiocytic lymphoma (monocytic sarcoma). Am J Dermatopathol. 1992;14:511–7.
Badalian-Very G, Vergilio JA, Degar BA, et al. Recurrent BRAF mutations in Langerhans cell histiocytosis. Blood. 2010;116:1919–23.
Nelson DS, Quispel W, Badalian-Very G, et al. Somatic activating ARAF mutations in Langerhans cell histiocytosis. Blood. 2014;123:3152–5.
Diamond EL, Durham BH, Haroche J, et al. Diverse and targetable kinase alterations drive histiocytic neoplasms. Cancer Discov. 2016;6:154–65.
Gadner H, Grois N, Potschger U, et al. Improved outcome in multisystem Langerhans cell histiocytosis is associated with therapy intensification. Blood. 2008;111:2556–62.
Hyman DM, Puzanov I, Subbiah V, et al. Vemurafenib in multiple nonmelanoma cancers with BRAF V600 mutations. N Engl J Med. 2015;373:726–36.
Haroche J, Cohen-Aubart F, Emile JF, et al. Dramatic efficacy of vemurafenib in both multisystemic and refractory Erdheim-Chester disease and Langerhans cell histiocytosis harboring the BRAF V600E mutation. Blood. 2013;121:1495–500.
Gadner H. Treatment of adult-onset Langerhans cell histiocytosis—is it different from the pediatric approach? Ann Oncol. 2010;21:1141–2.
Histiocyte Society: The Histiocyte Society--home page. 2009.
De Leon Caces DB, Daniel S, Paredes-Tejada JM, et al. Spontaneous regression of follicular dendritic cell sarcoma. J Clin Oncol. 2012;30:e24–6.
Wang H, Su Z, Hu Z, et al. Follicular dendritic cell sarcoma: a report of six cases and a review of the Chinese literature. Diagn Pathol. 2010;5:67.
Author information
Authors and Affiliations
Rights and permissions
Copyright information
© 2016 Springer International Publishing Switzerland
About this chapter
Cite this chapter
Brennan, M.F., Antonescu, C.R., Alektiar, K.M., Maki, R.G. (2016). Sustentacular Tumors of Lymph Tissue. In: Management of Soft Tissue Sarcoma. Springer, Cham. https://doi.org/10.1007/978-3-319-41906-0_23
Download citation
DOI: https://doi.org/10.1007/978-3-319-41906-0_23
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-41904-6
Online ISBN: 978-3-319-41906-0
eBook Packages: MedicineMedicine (R0)